» Articles » PMID: 37097079

The Diagnosis and Treatment of Osteosarcoma and Ewing's Sarcoma in Children and Adolescents

Overview
Date 2023 Apr 25
PMID 37097079
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteosarcoma and Ewing's sarcoma in children and adolescents require age-specific interdisciplinary diagnosis and treatment to achieve optimal therapeutic outcomes.

Methods: The diagnosis and treatment of malignant bone tumors in childhood and adolescence are presented in the light of publications retrieved by a selective search, pertinent guidelines, and the authors' extensive experience in an interdisciplinary cancer center.

Results: Bone sarcomas make up approximately 5% of all malignancies in children and adolescents; the most common types are Ewing's sarcoma and osteosarcoma. Patients are often not referred to a specialized center until long after the onset of symptoms, as they and their physicians rarely consider the possibility of a bone tumor, and the symptoms are often trivialized. Bone pain of unknown origin, swelling, and functional limitations should be investigated with conventional x-rays. Lesions of unclear origin should be biopsied after a meticulous clinical and radiologic evaluation. Multimodal treatment consists of neo - adjuvant chemotherapy, limb-preserving resection if possible, and radiotherapy where indicated. In multicenter studies, patients with osteosarcoma achieve event-free survival in 64% of cases if their disease is localized, and 28% if it is metastatic; the corresponding figures for patients with Ewing's sarcoma are 80% and 27%, respectively.

Conclusion: With implementation of the current treatment recommendations, most children and adolescents with malignant bone tumors can be treated successfully with curative intent. These patients should be referred to a sarcoma center for diagnosis and treatment.

Citing Articles

A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023.

Shen Y, Shao X, Chen J, Tang X Discov Oncol. 2025; 16(1):255.

PMID: 40019638 PMC: 11871176. DOI: 10.1007/s12672-025-02007-2.


Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics.

Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J Front Immunol. 2025; 16:1539396.

PMID: 39991153 PMC: 11842356. DOI: 10.3389/fimmu.2025.1539396.


Advancements in nanoparticles-based therapeutic approaches for osteosarcoma: Insights from catechins-modified selenium-doped hydroxyapatite: A review.

Degang T, Wei X, Jianying S, Aining L, Chenyu J, Haitang L Medicine (Baltimore). 2025; 104(7):e41489.

PMID: 39960964 PMC: 11835080. DOI: 10.1097/MD.0000000000041489.


Daidzin improves the cisplatin chemosensitivity for osteosarcoma via binding to β-catenin protein and suppressing the wnt pathway.

Wang P, Lu H, Zhang C, Wang R, Chen X, Qiao L Sci Rep. 2025; 15(1):5484.

PMID: 39953179 PMC: 11829052. DOI: 10.1038/s41598-025-89766-8.


Clinical and Pathological Profile of Children and Adolescents with Osteosarcoma.

Ivan A, Cojocaru E, Sirbu P, Al Namat D, Tirnovanu S, Butnariu L Diagnostics (Basel). 2025; 15(3).

PMID: 39941196 PMC: 11817002. DOI: 10.3390/diagnostics15030266.


References
1.
Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A . Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer. 2016; 61:128-36. DOI: 10.1016/j.ejca.2016.03.075. View

2.
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E . Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2018; 20(1):120-133. DOI: 10.1016/S1470-2045(18)30742-3. View

3.
Gotta J, Bielack S, Hecker-Nolting S, Sorg B, Kevric M, Salzmann-Manrique E . When Your Ankle Becomes a Knee - Long-Term Functional Outcome and Quality of Life with a Rotationplasty after Resection of Malignant Limb Tumors. Klin Padiatr. 2021; 234(3):154-162. DOI: 10.1055/a-1681-1916. View

4.
Windhager R, Funovics P, Panotopoulos J, Hobusch G, Schinhan M . [Growing prostheses after sarcoma resection in children and adolescents]. Orthopade. 2019; 48(7):563-571. DOI: 10.1007/s00132-019-03753-2. View

5.
Goorin A, Gebhardt M, Andersen J, WILKINSON R, Delorey M, Watts H . Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III. J Clin Oncol. 1987; 5(8):1178-84. DOI: 10.1200/JCO.1987.5.8.1178. View